Presentation by FDA’s Larry Kessler regarding effort to develop new guidelines for risk based pre-market reviews by FDA’s Office of Science and Technology. A key emphasis is on evaluation and justification of residual risk (what we at SoftwareCPR often refer to as establishing a safety case).